Nivolumab vs Gemcitabine or Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
J. Clin. Oncol 2021 Sep 02;[EPub Ahead of Print], J Hamanishi, N Takeshima, N Katsumata, K Ushijima, T Kimura, S Takeuchi, K Matsumoto, K Ito, M Mandai, H Nakai, N Sakuragi, H Watari, N Takahashi, H Kato, K Hasegawa, K Yonemori, M Mizuno, K Takehara, H Niikura, T Sawasaki, S Nakao, T Saito, T Enomoto, S Nagase, N Suzuki, T Matsumoto, E Kondo, K Sonoda, S Aihara, Y Aoki, A Okamoto, H Takano, H Kobayashi, H Kato, Y Terai, A Takazawa, Y Takahashi, Y Namba, D Aoki, K Fujiwara, T Sugiyama, I KonishiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.